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PCSK9 regulates lowdensity lipoprotein receptor (LDLR) lev-
els and consequently is a target for the prevention of atheroscle-
rosis and coronary heart disease. Here we studied the interac-
tion, of LDLR EGF(A/AB) repeats with PCSK9. We show that
PCSK9 binds the EGF(AB) repeats in a pH-dependent manner.
Although the PCSK9 C-terminal domain is not involved in
LDLR binding, PCSK9 autocleavage is required. Moreover, we
report the x-ray structure of thePCSK9C-EGF(AB) complex at
neutral pH. Compared with the low pH PCSK9-EGF(A) struc-
ture, the new structure revealed rearrangement of the EGF(A)
His-306 side chain and disruption of the salt bridge with PCSK9
Asp-374, thus suggesting the basis for enhanced interaction at
low pH. In addition, the structure of PCSK9C bound to
EGF(AB)H306Y, a mutant associated with familial hypercho-
lesterolemia (FH), reveals that the Tyr-306 side chain forms a
hydrogen bond with PCSK9 Asp-374, thus mimicking His-
306 in the low pH conformation. Consistently, Tyr-306 con-
fers increased affinity for PCSK9. Importantly, we found that
although the EGF(AB)H306Y-PCSK9 interaction is pH-inde-
pendent, LDLRH306Y binds PCSK9 50-fold better at low pH,
suggesting that factors other than His-306 contribute to the
pH dependence of PCSK9-LDLR binding. Further, we deter-
mined the structures of EGF(AB) bound to PCSK9C con-
taining the FH-associated D374Y and D374H mutations,
revealing additional interactions with EGF(A) mediated by
Tyr-374/His-374 and providing a rationale for their disease
phenotypes. Finally, we report the inhibitory properties of
EGF repeats in a cellular assay measuring LDL uptake.
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9)4
has recently emerged as a major regulator of low density
lipoprotein (LDL) cholesterol levels in plasma and conse-
quently as an important determinant of cardiovascular health
in humans. The link between cardiovascular disease andPCSK9
was initially made following the discovery that the PCSK9mis-
sensemutations, S127R and F216L (1), and later, D374Y (2), are
associated with a form of autosomal dominant hypercholester-
olemia, a risk factor for coronary heart disease. Subsequently,
two PCSK9 nonsense mutations (Y142X and C679X) (3) and
several missense mutations (R46L, G106R, N157K, G236S,
R237W,L253F,N354I andA443T) (4–6) have been found to be
associated with hypocholesterolemia. Remarkable degrees of
protection against coronary heart disease were observed in
humans heterozygous for the mutations Y142X and C679X
(88% reduced incidence) and by R46L (47% reduced incidence)
(7). Consequently, PCSK9 represents a novel therapeutic target
for the prevention of premature atherosclerosis and coronary
heart disease, and an understanding of its mechanism of action
is of significant medical interest.
PCSK9 is the ninth member of the mammalian proprotein
convertase family of serine proteases. The translated pro-
protein includes an N-terminal signal sequence directing its
secretion (residues 1–30), a prodomain (residues 31–152), a
catalytic domain (residues 153–451), and a cysteine-rich
C-terminal domain (residues 452–692) (8). PCSK9 under-
goes autocleavage in the endoplasmic reticulum, and only
the processed form is secreted (8, 9). The autocleavage event
occurs between residues Gln-152 and Ser-153 and is depend-
ent on a canonical triad of catalytic residues (Asp-186, His-
226, and Ser-386). Unlike other members of the proprotein
convertase family, following autocleavage the PCSK9 prodo-
main remains associated with the catalytic and C-terminal
domains of the protein. The three-dimensional structure of
this stable PCSK9 heterodimer as determined by x-ray crys-
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tallography reveals a large noncovalent interface between
the prodomain and the catalytic domain (10–12). A note-
worthy feature of the interaction is that after autocleavage
the C-terminal residues of the prodomain occupy the active
site of the catalytic domain inhibiting further enzymatic
activity by PCSK9.
PCSK9 is expressed predominantly in the liver, small intes-
tine, and kidney (8). Recently, several independent groups have
shown that processedPCSK9binds to the LDL receptor (LDLR)
and decreases total and cell surface LDLR levels by directing the
receptor to the lysosomes for degradation (13). Although an
intracellular mechanism preceding secretion is not formally
excluded, the introduction of PCSK9 into the circulation of
mice through parabiosis reduces hepatic LDLR levels (14), as
does the injection into mice of recombinant PCSK9 (15, 16),
suggesting that circulating PCSK9 can act by binding to LDLR
on the cell surface. This in vivo study is further supported by in
vitro experiments in which the addition of PCSK9 to cultured
cell medium results in LDLR degradation (9, 14) and decreases
LDL uptake (17). Prior to its degradation, the PCSK9-LDLR
complex is internalized by endocytosis in a manner dependent
on clathrin (18) and on the association of a cytosolic region of
the LDLRwith theARHprotein (14). A plausiblemechanism of
action leading to LDLR degradation rather than its vesicular
recycling has been proposed following binding studies demon-
strating that PCSK9 binds the LDLR ectodomain with 100-
fold higher affinity at the acidic pH of late endosomes/lyso-
somes compared with the neutral pH of the cell surface (10, 12,
17, 19). The enhanced affinity at acidic pH suggests that, differ-
ently from the LDLR-LDL complex, the LDLR-PCSK9 complex
does not dissociate in the endosomes, thus preventing LDLR
recycling and instead leading to shuttling of the complex to the
lysosomes for degradation. Of note, the PCSK9D374Y mutant (a
“gain-of-function” (GOF) mutant associated with hypercholes-
terolemia) was shown to bind the LDLR with 6–30-fold higher
affinity thanwild type (WT) PCSK9, supporting the notion that
a tight interaction between PCSK9 and LDLR promotes degra-
dation of the receptor.
Immunoprecipitation and Western blotting analyses were
used by Hobbs and colleagues (19) to demonstrate that the epi-
dermal growth factor-like repeat A (EGF(A)) of the LDLR is
sufficient for PCSK9 binding. Recently, the x-ray crystal struc-
ture of the PCSK9-EGF(AB) complex, crystallized at pH 4.8,
was also reported (20). Here we extend these data by character-
izing the interaction, at both neutral and acidic pH, of the
LDLR ectodomain and of the EGF(A) and EGF(AB) repeats
of the LDLR with both full-length PCSK9 and a form of
PCSK9 lacking the C-terminal domain (PCSK9C). More-
over, we present the neutral pH x-ray crystal structure of
WT PCSK9C bound to EGF(AB) and the structures of
mutant forms of these proteins associated with familial
hypercholesterolemia (FH), including EGF(AB) bound to
PCSK9CD374Y and PCSK9CD374H, and of WT PCSK9C
bound to EGF(AB)H306Y (21–24). These structures reveal the
molecular basis by which the mutations lead to FH. Further,
comparisons of the previously reported low pH PCSK9-
EGF(AB) complex structure with the structures reported
here, and accompanying binding data, provide the molecular
basis for the pH dependence of the PCSK9-EGF(A) interac-
tion. Finally, we characterize the inhibitory properties of the
isolated EGF repeats in a cellular LDL uptake assay demon-
strating that in vitro these LDLR subfragments are sufficient
to inhibit the LDLR-lowering activity mediated by PCSK9.
EXPERIMENTAL PROCEDURES
Preparation of Expression Plasmids
Full-length human PCSK9 with C-terminal V5 and His6
epitope tags was cloned into the pcDNA3.1-F1-WT plasmid
and expressed in stably transfected HEK293 cell lines as
described previously (17). A modified form of the PCSK9
expression plasmidwas also constructed to encode PCSK9with
the AviTag peptide sequence (GLNDIFEAQKIEWHE)
between the V5 and His6 tags, enabling site-specific biotinyla-
tion on the Lys (K) residue (underlined). The human LDLR
ectodomain (residues 1–720) was cloned into the pDEST40
plasmid (Invitrogen) and the H306Y mutation was introduced.
DNA fragments encoding the proteins PCSK9C (Gln-31—
Ala-451) and N-PCSK9C (Ala-53—Ala-451) were sub-
cloned from the pcDNA3.1-F1-WT plasmid into the pETM-10
expression plasmid (EMBL Heidelberg, Germany) which was
subsequently modified to encode a C-terminal His6 tag. The
EGF(A) (Gly-293—Glu-332) and EGF(AB) (Gly-293—Lys-372)
domains from human LDLR (numbering excludes N-terminal
signal peptide) were cloned into the pETM-11 expression plas-
mid, which allows removal of the His6 tag by digestion with
tobacco etch virus protease (EMBL Heidelberg). All point
mutationswere introducedusing theQuikChange site-directed
mutagenesis kit (Stratagene).
Purification of Recombinant PCSK9, Biotinylated PCSK9,
PCSK9C, LDLR EGF Domain Proteins, and LDLRH306Y
Ectodomain
Full-length PCSK9 and PCSK9-AviTag were expressed fol-
lowing stable transfection of HEK293 cells and purified as
described previously (17). Purified PCSK9-AviTag was biotin-
ylated in vitro with biotin ligase following the manufacturer’s
instructions (Avidity, Inc.). The PCSK9C, N-PCSK9C,
EGF(A), and EGF(AB) proteins were produced in Escherichia
coli BL21 cells with induction of protein production by 0.4 mM
isopropyl 1-thio--D-galactopyranoside and subsequent incu-
bation with shaking at 18 °C overnight. After cell lysis, proteins
were purified from the soluble fraction by nickel affinity chro-
matography. The EGF(A) and EGF(AB) proteins were then
reduced by the addition of 0.1 M dithiothreitol and subjected to
a 72-h oxido-shuffling refolding protocol by dialysis against 50
mMTris-HCl, pH8.3, 5% glycerol, 5mMCaCl2, 3mM L-cysteine,
and 0.3 mM L-cystine as described previously (25). The N-ter-
minal His6 tag was removed from the EGF(A/AB) proteins by
overnight incubation at room temperature with a solubility-
enhanced tobacco etch virus protease (26). All proteins were
purified by size exclusion chromatography using a Superdex-75
(16/60 or 26/60) column equilibrated in 40 mM Tris-HCl, pH
7.5, 200 mM NaCl, 5% glycerol, 5 mM CaCl2 for EGF proteins
and in 40 mM Tris-HCl, pH 8.0, 200 mM NaCl, 5% glycerol, 0.1
mM CaCl2, 0.05% n-octyl--glucoside for PCSK9C and
N-PCSK9C.
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The LDLRH306Y protein was produced in HEK293-EBNA
cells following transient transfection. Cell supernatants were
exchanged by ultrafiltration into buffer containing 50 mM
sodium phosphate, pH 8.0, 300 mM NaCl, 1 mM CaCl2, and the
protein was purified by metal affinity chromatography
(TALON resin, Clontech), followed by ion exchange chroma-
tography (ResourceQ, GEHealthcare) and size exclusion chro-
matography (Superdex 200, GE Healthcare) in 25 mM Hepes,
pH 8.0, 150 mM NaCl, and 1 mM CaCl2.
Surface Plasmon Resonance (SPR)
All SPR experiments were performed using Biacore instru-
ments at 25 °C. Running buffers contained 150 mMNaCl, 1 mM
CaCl2, 0.005% (v/v) P-20 surfactant, and either 25 mM Hepes,
pH 7.4, or 25 mM sodium acetate, pH 5.7. For studies of
EGF(AB) binding to PCSK9, the purified full-length C-termi-
nally biotinylated PCSK9 was noncovalently immobilized on a
streptavidin-coated sensor surface (SA chip, GE Healthcare).
For studies of PCSK9 or PCSK9C binding to LDLR proteins,
the purified full-length LDLR (WT or H306Y mutant) was
covalently immobilized by amine coupling to a carboxymethy-
lated dextran sensor surface (CM5 chip, GE Healthcare).
Binding constantswere obtained froma series of injections at
50 l/min of analyte (PCSK9, PCSK9C, or EGF(AB)) at con-
centrations up to 2 M. Following injections of PCSK9 or
PCSK9C, LDLR-coupled sensor chip surfaces were regener-
ated with a 5-s injection of 30 mM NaOH. Following injections
of EGF(AB), the PCSK9-coupled sensor chip surfacewas regen-
erated with a 25-s injection of 5 mM EDTA followed by a 30-s
injection of 6 mM CaCl2. Data were analyzed using BIAevalua-
tion software, with reference sensorgrams subtracted from
experimental sensorgrams to yield curves representing specific
binding. Steady-state analysis was used to plot equilibrium
binding response (Req) against analyte concentration in order
to obtain thermodynamic dissociation constants (KD). For each
series, simultaneous fitting of dissociation curves was used to
obtain koff, which was then used to obtain kon (KD koff/kon) as
described previously (17).
Time-resolved Fluorescence Resonance Energy
Transfer (TR-FRET)
TR-FRET experiments were performed essentially as
described previously (17) using 4 nM Eu3-labeled LDLR
ectodomain and 10 nM Alexa Fluor 647-labeled PCSK9. Reac-
tions were performed at 20 °C in 50 l of buffer containing 10
mM Hepes, pH 7.4, 150 mM NaCl, 0.1 mM CaCl2, and 0.05%
(w/v) bovine serum albumin. Disruption of the PCSK9-LDLR
interactionwas assessed in titrations inwhich putative compet-
itor proteins, typically in concentration ranges of 0.1 nM to 2.5
M, were added to the reaction mixture with incubations for
16 h prior to fluorescence measurements. IC50 values were
determined from triplicate experiments by fitting data to a sig-
moidal dose-response curve using nonlinear regression
(GraphPad Software Inc.). For proteins that did not give full
titrations, data were fitted with the dose-response minimum
defined by the signal obtained in the presence of 1 mM EDTA,
which renders LDLR inactive.
LDL Uptake Assay
LDL uptake was measured in HEK293 cells stably expressing
the pcDNA3.1 vector alone as described previously (17). The
only experimental difference is that Alexa Fluor 546-labeled
LDL, rather than LDL labeled with 3,3-dioctadecylindocarbo-
cyanine (Dil), was used to follow cellular LDL uptake; labeling
was performed as described previously (27). The inhibition of
PCSK9 activity was assessed in titrations in which putative
competitor proteins, in the nanomolar to micromolar concen-
tration range, were added to the growth medium at the same
time as PCSK9 followed by a 6.5-h incubation at 37 °C. The
amount of competitor protein required for half-maximal inhi-
bition of PCSK9 (IC50) was determined by fitting data to a sig-
moidal dose-response curve using nonlinear regression
(GraphPad Software Inc.).
Epitope Excision andMass Spectrometry
Immobilization of EGF(AB) on Sepharose Beads andComplex
Formation with PCSK9D374Y—CNBr-activated Sepharose
beads (50 mg/ml) were resuspended in 1 mM HCl. A 100-l
volume of beads was packed into two 0.8-ml micro-columns
and washed extensively with 1 mM HCl. The two columns
were washed with 20ml of 0.1 MNaHCO3, 0.5 MNaCl, pH 8.3
(equilibration buffer), and the coupling reaction was per-
formed for 2 h at 37 °C using either 50 g of EGF(AB) in 200
l of equilibration buffer or simply the equilibration buffer
in the absence of EGF(AB) (control column). After coupling
the columns were washed with 0.1 M Tris-HCl, pH 8.0, 0.5 M
NaCl, then were incubated in the same buffer at 37 °C for 2 h
to achieve complete deactivation of the Sepharose beads, and
finally were washed with phosphate-buffered saline, pH 7.4.
EGF(AB)-coupled beads and control beads were incubated
with 0.1 g/l PCSK9D374Y in 200 l of phosphate-buffered
saline for 2 h at 37 °C. The beads were then washed with 20
ml of phosphate-buffered saline.
Epitope Excision with Endoproteases—The complex-bound
beads and the control beadswere incubatedwith several endopro-
teases: chymotrypsin andAspN (1g/100l), trypsin (0.5g/100
l), GluC (5 g/100 l), and aminopeptidase (100 g/100 l).
Enzyme addition was repeated until the mass spectrum profile of
the peptides bound to the EGF(AB)-coupled beads remained
unchanged. The enzymes were added in the following order in
four independent experiments: 1) chymotrypsin followed by tryp-
sin, 2) GluC and aminopeptidase, 3) chymotrypsin followed by
AspN, 4) trypsin followed by aminopeptidase.
MALDI-TOFMSAnalysis—Thepeptides associatedwith the
Sepharose beads were analyzed by MALDI-TOF MS. 1 l of
EGF(AB)-coupled beads was deposited on aMALDI target, and
a saturated solution of sinapinic acid (3,5-dimethoxy-4-hy-
droxycinnamic acid; Aldrich) in 50% acetonitrile and 1% triflu-
oroacetic acid was added. The spectra of positive ions were
recorded in linear mode on a MALDI-TOF mass spectrometer
(Voyager-STR, Perseptive Biosystem, Inc., Framingham, MA)
equipped with a delayed extraction device and a nitrogen laser
( 337 nm). Approximately 500 shots were averaged for each
spectrum acquired. External calibration was performed with
Glu1-FibrinopeptideB, ACTH-(1–17), ACTH-(18–39), and
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ACTH-(7–38) using themonoprotonated ion of themonomers
with average mass-to-charge (m/z) ratios. The difference
between the calculated average mass and the experimental
mass determination (0.05–0.1%) was consistent with the accu-
racy of MALDI-TOF mass spectrometry in linear mode.
N-PCSK9C-EGF(AB) Complex Crystallization and Structure
Determination
Purified N-PCSK9C and EGF(AB) WT or mutant pro-
teins were mixed in a 1:3 molar ratio, and the complex was
separated from excess EGF(AB) by size exclusion chromatog-
raphy on a Superdex-200 (26/60) column equilibrated in 40mM
Tris-HCl, pH 8.0, 200 mMNaCl, 20 M CaCl2, and 5% glycerol.
The complex was concentrated to 4 mg/ml in a buffer contain-
ing 40mMTris-HCl, pH8.0, 100mMNaCl, 20MCaCl2, and 5%
glycerol and was crystallized by the vapor diffusion method.
Crystals of WT N-PCSK9C with WT EGF(AB) were
obtained using a reservoir containing 0.1 M Hepes, pH 7.5, 10%
(v/v) 2-propanol, and 20%polyethylene glycol 4000.Crystals for
all other complexes were obtained using a reservoir containing
0.1 M Hepes, pH 7.5, 10% polyethylene glycol 8000, and 8%
ethylene glycol. Before data collection, crystalswere transferred
into stabilizing reservoir solutions containing increased precip-
itant concentration and 20% glycerol as cryoprotectant and
were flash-frozen in liquid nitrogen.
X-ray diffraction data were collected at 100 K on the ID-23
beam line at the European Synchrotron Radiation Facility
(ESRF, Grenoble, France). Diffraction data were processedwith
MOSFLM (28), and the CCP4 suite of programs (29) was used
for further data processing and analysis. All crystals belong to
the P43212 space group and contain one N-PCSK9C-
EGF(AB) complex per asymmetric unit and 65–70% solvent.
The N-PCSK9C-EGF(AB) WT structure was determined
by themolecular replacementmethodwith PHASER (30) using
the structure of PCSK9 (2QTW) with the C-terminal domain
removed as a search model. After rigid body refinement,
2FoFc electron density maps were calculated and used to
build the LDLR EGF(A) domain. Model building was per-
formedwithin Coot (31), and REFMAC (32) was used for struc-
ture refinement defining one TLS group per protein chain. The
final models include residues Thr-60—Ser-447 of PCSK9 and
Gly-293—Glu-332 of EGF(A). No electron density was
observed for the EGF(B) domain, which is presumed to be dis-
ordered in the crystals. The amount of solvent-accessible sur-
face area buried by protein complex formation was determined
using the PISA software (33).
RESULTS
Processed PCSK9 Binds to the EGF(AB) Repeats of LDLR in a
pH-dependent Manner—It has been reported that the EGF(A)
domain of the LDLR receptor is sufficient to bind to PCSK9 (19,
20). To probe the affinities of the PCSK9-EGF(A) and PCSK9-
EGF(AB) interactions and to compare them with the affinity of
the PCSK9-LDLR complex, we used a TR-FRET assay. In this
assay, EGF(A) and EGF(AB) competed efficiently with labeled
LDLR for binding to labeled PCSK9, showing inhibition con-
stants (IC50) of 1255  7 and 367  94 nM, respectively, com-
pared with an IC50 of 218 41 nM when using unlabeled LDLR
as a competitor (Fig. 1A). Thus, at neutral pH the EGF(AB)
fragment bound to PCSK9 with an affinity similar to that of the
full-length receptor.
Using SPR we showed previously that at neutral pH full-
length WT PCSK9 binds to the LDLR ectodomain (residues
22–788) with a high nanomolar dissociation constant (KD) and
that this affinity is enhanced150-fold at acidic pH (17). Here
we used SPR to examine the effect of pH on the interaction
between PCSK9 and EGF(AB). Although covalently immobi-
lized EGF(A) or EGF(AB) displayed specific binding to both
PCSK9 and PCSK9C, it was not possible to establish reliable
surface regeneration conditions after successive analyte injec-
tions, and hence stepwise titrations in this format (EGF(A) or
EGF(AB) proteins immobilized on sensor chip) were not feasi-
ble. Nevertheless, comparing equimolar (200 nM) protein injec-
tions at neutral or acidic pH, we consistently observed a greater
response at acidic pH for binding of both PCSK9 and PCSK9C
to immobilized EGF(A) or EGF(AB) (supplemental Fig. 1A).
Similarly, the PCSK9D374Ymutant also showed enhanced bind-
ing to immobilized EGF(A) or EGF(AB) at acidic pH (supple-
mental Fig. 1B). To confirm these observations and to obtain
KD values for the PCSK9-EGF(AB) interaction, we performed
the reciprocal SPR analysis, in which a biotinylated form of
PCSK9 was immobilized on a streptavidin-coated sensor chip.
For this purpose, a PCSK9 protein with an additional C-termi-
nal peptide sequence enabling site-specific in vivo biotinylation
was prepared; the advantage was that this form of PCSK9 is
immobilized on the sensor chip via the biotinylated C-terminal
extension, with a reduced possibility of masking potential
EGF(AB) binding sites. As observed previously for full-length
LDLR at neutral pH, the EGF(AB) fragment bound to the
FIGURE 1. TR-FRET analyses of the PCSK9-LDLR interaction and its inhibi-
tion. A, in a TR-FRET assay at neutral pH, EGF(A) and EGF(AB) compete with
the LDLR ectodomain for binding to PCSK9with low/submicromolar IC50 val-
ues. B, in the TR-FRET assay, full-length WT PCSK9 and WT PCSK9C are
equipotent at disrupting the interaction of labeled WT PCSK9 with labeled
LDLR, demonstrating that the C-terminal domain of PCSK9 is not required for
binding. In contrast with WT PCSK9C, an unprocessed form of PCSK9C
(S386A) was unable to disrupt the interaction.
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immobilized PCSK9 with a high nanomolar binding affinity
(KD 340 nM; Table 1). Moreover, the affinity of the EGF(AB)-
PCSK9 interaction was greater at acidic pH compared with
neutral pH, exhibiting an 3-fold enhancement in binding
(KD  140 nM). Thus, in agreement with the TR-FRET assay
results described above, the SPR data confirmed that the LDLR
EGF(AB) fragment was sufficient for high affinity binding to
PCSK9 and that the interaction was pH-dependent.
The PCSK9 C-terminal Domain Is Not Involved in LDLR
Binding—A previous study had suggested that PCSK9 requires
its C-terminal domain for LDLR binding (10). To evaluate the
contribution of this region of PCSK9 for receptor binding we
expressed in E. coli a truncated form of PCSK9 (PCSK9C; res-
idues 31–451) that lacks the entire C-terminal domain and
tested this purified, autoprocessed protein in the TR-FRET
assay. We found that the PCSK9C protein was essentially as
efficient as full-length PCSK9 at disrupting the PCSK9-LDLR
interaction (Fig. 1B), exhibiting IC50 values of 110 and 80
nM, respectively. Further, SPR studies at neutral pH also
revealed that PCSK9C bound to LDLR with an affinity (KD
196 nM; Table 1) comparable with that exhibited by full-length
PCSK9. Because of its poor solubility at low pH, the binding
constants could not be determined for PCSK9C at pH 5.7.
Together these results demonstrate that at neutral pH the
PCSK9 C-terminal domain (residues 452–692) is not involved
in receptor binding.
PCSK9 Autocleavage Is Required for Effective Binding to
LDLR—To assess whether PCSK9 autoprocessing is required
for LDLR binding, we also expressed and purified an unproc-
essed form of PCSK9C where the active site catalytic residue
Ser-386 was mutated to alanine. The unprocessed S386A
PCSK9C protein was unable to disrupt the PCSK9-LDLR
complex evenwhen added in a 500-foldmolar excess compared
with processed PCSK9 (Fig. 1B). These results are consistent
with a previous report stating that an uncleaved full-length cat-
alytically inactive mutant PCSK9 was unable to bind LDLR in
vitro (34), thus reinforcing the concept that PCSK9 processing
is required for LDLR binding.
The LDLR EGF(AB) Domains Bind Tightly to a Region of the
PCSK9 Catalytic Domain—To determine the region of PCSK9
responsible for high affinity binding to EGF(AB), we employed
the “epitope excision” strategy (35). To maximize formation of
the EGF(AB)-PCSK9 complex, the PCSK9D374Y mutant was
used in these experiments. The epitope excision analysis
involved several steps. First, EGF(AB) was covalently immobi-
lized on CNBr-activated Sepharose beads and incubated with
full-length PCSK9. Then, the complex was subjected to endo-
protease digestion under controlled conditions followed by a
washing step. The regions of PCSK9 that bound to EGF(AB),
that were protected from digestion, and that resisted washing
were identified by direct analysis of the beads by MALDI MS.
After one cycle of epitope excision using chymotrypsin, two
predominant peptides were found associated with EGF(AB);
they were identified as PCSK9 residues Asn-157—Phe-216 and
Arg-167—Phe-216 (Fig. 2A). The latter steps of the epitope
excision strategy were then repeated using additional endo-
and exoproteases, enabling refinement of the results. Thus,
after further cycles of digestion with trypsin, GluC, aminopep-
tidase, and AspN, the minimal region protected by EGF(AB)
spanned PCSK9 residues Asp-175 to Glu-210 (Fig. 2B).
Neutral pH X-ray Structures of Wild Type PCSK9C-
EGF(AB) Complexes and Site-directed Mutagenesis—To char-
acterize the molecular details of the interaction occurring
between PCSK9 and LDLR we crystallized the PCSK9C-
EGF(AB) complex at neutral pH. The structurewas determined
by the molecular replacement method and was refined to 2.4 Å
resolution (Table 2). No interpretable electron density was
observed for the EGF(B) domain, suggesting that it is disor-
dered in the crystals. Overall the PCSK9 and EGF(A) structures
FIGURE 2. Epitope excision and mass spectrometry analyses. A, the
MALDI-TOF mass spectrum of EGF(AB) beads (left) and control beads (right)
after the first cycle of epitope excision employing chymotrypsin digestion.
Peaks at m/z 5714.2 and 6954.3 result from ions corresponding to PCSK9
residues Arg-167—Phe-216 and Asn-157—Phe-216, respectively. B, sche-
matic diagram of the PCSK9 domain organization and a summary of the data
obtained by MS analyses. The minimal PCSK9 peptide sequence bound to
EGF(AB)-coupled beads after multiple endoprotease incubations is shown.
The arrows indicate protease cleavage sites and are color-coded. Green, chy-
motrypsin (F,W, L, Y); red, trypsin (R, K); blue, trypsin aminopeptidase; azure,
chymotrypsin trypsinGluC (E); purple, chymotrypsin trypsinGluC
aminopeptidase;black, chymotrypsinAspN (D);pink, chymotrypsin tryp-
sin (bracketed letters indicate cleavage site specificities).
TABLE 1
Summary of binding data from surface plasmon resonance studies
“Ligand” refers to the immobilized protein, and “Analyte” refers to the protein injected in solution. §, in this assay format, kon and koff were not readily determined by fitting
to the 1:1 Langmuir model, likely because of mass transfer limitation and incomplete dissociation of EGF(AB) from the surface. ND, not determined (the PCSK9C protein
was not sufficiently stable in solution at acidic pH to perform these measurements).
Ligand Analyte Neutral pH Acidic pHKD koff kon KD koff kon
nM s1 M1s1 nM s1 M1s1
PCSK9 EGF(AB) 340 § § 140 § §
LDLR PCSK9C 196 1.9 103 9.7 103 ND ND ND
LDLRH306Y PCSK9 330 1.3 103 3.8 103 7 0.6 103 8.6 105
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are very similar to their respective apo-structures and to the
recently determined structure of the PCSK9-EGF(A) complex
crystallized at pH 4.8 (r.m.s.d. values for C atoms are 0.4 Å for
the prodomain, 0.6 Å for the catalytic domain, and 0.7 Å for
EGF(A)) (20).
The EGF(A) domain makes contacts only with the catalytic
domain of PCSK9, on which it buries 468 Å2 of solvent-acces-
sible area (Fig. 3). The interaction
involves the formation of an anti-
parallel -sheet between EGF(A)
and the exposed side of a -hairpin
loop of PCSK9 (Fig. 3C). Notably,
the tip of this loop is the site of the
D374Y GOF mutation, which con-
fers enhanced affinity to the interac-
tion with LDLR. Of note, the N-ter-
minal amino group of Ser-153
interacts with EGF(A) (Fig. 4).
Importantly, the latter interaction
can occur only with the processed
form of the enzyme; this is consist-
ent with the lack of LDLR binding to
unprocessed PCSK9C reported
above.
Site-directed mutagenesis was
then used to evaluate the contribu-
tion to high affinity binding of
amino acids at the complex inter-
face.When compared with theWT
PCSK9C protein, the PCSK9C
mutants R194A and D238A showed
a greatly reduced ability to disrupt
the PCSK9-LDLR complex (Table
3), confirming the key role of these
two residues for EGF(A) binding. In
addition, to assess the contribution
toward EGF(A) binding of the
PCSK9 P -helix (generated at the
N terminus of the catalytic domain
following autocleavage), we ex-
pressed the PCSK9C P mutants
P155G,W156L,N157K, L158A, and
I161A. These mutations are pre-
dicted to interfere with the positioning of the P-helix (Fig. 4).
The PCSK9C P mutant proteins showed a strongly reduced
ability to disrupt the PCSK9-LDLR interaction (Table 3), con-
firming the importance of the P -helix for LDLR binding.
Interestingly, N157K is a naturally occurring LOF mutation
associated with low plasma levels of LDL cholesterol (4). Thus,
FIGURE3.Crystal structureof thePCSK9C-EGF(AB) complex.Ribbon (A) and surface (B) representations, in
the sameorientation, of the complex formedbetweenPCSK9CandEGF(A) (yellow). EGF(A) contacts PCSK9via
the catalytic domain (red) but not the prodomain (blue). The P helix, which is part of the catalytic domain, is
shown in pink. Dotted lines represent PCSK9 residues for which no electron density was observed. C, transpar-
ent surface representation of PCSK9C; blue-labeled patches indicate residues contacted by EGF(A) (yellow
ribbon; the yellow sphere is the Ca2 ion). Contacts are all less than 4 Å. Asp-374 (PCSK9) is at the tip of a
-hairpin loop. EGF(A) His-306 adopts a conformation that does not allow interaction with Asp-374 at neutral
pH. Ser-153 is the N terminus of the PCSK9 catalytic domain generated upon autocleavage. Hydrogen bonds
are established between side chain atoms of the following pairs of residues fromPCSK9 and EGF(A): Arg-194 to
Asp-310 and Asn-295, Asp-238 to Asn-295, Thr-377 to Asn-309 and Asp-310, and between backbone atoms for
Thr-377 to Asp-310 and Phe-379 to Cys-308. D, transparent surface representation of EGF(A); yellow-labeled
patches indicate residues contacted by PCSK9C. The protein is oriented as if removing PCSK9C from the
complex shown in panel C followed by a 180° y axis rotation.
TABLE 2
Data collection and refinement statistics
Values in parentheses correspond to the statistics for the highest resolution shell.
PCSK9C
EGF(AB)
PCSK9C
EGF(AB)H306Y
PCSK9CD374Y
EGF(AB)
PCSK9CD374H
EGF(AB)
PCSK9CD374A
EGF(AB)
Space group P43212 P43212 P43212 P43212 P43212
a, b, c (Å) 83.0, 83.0, 211.6 83.9, 83.9, 209.9 85.9, 85.9, 218.3 88.4, 88.4, 218.4 84.1, 84.1, 209.7
Resolution range (Å) 45–2.40 (2.53–2.40) 45–2.30 (2.42–2.30) 40–2.62 (2.76–2.62) 40–2.33 (2.46–2.33) 40–2.62 (2.76–2.62)
Reflections: total 19,1176 (25041) 233,390 (34295) 120,342 (17831) 156,846 (23254) 112647 (15328)
Reflections: unique 29,902 (4257) 33,566 (4874) 25,321 (3633) 37,593 (5426) 23184 (3341)
Completeness (%) 99.9 (99.9) 98.1 (99.7) 99.5 (99.9) 99.4 (99.8) 98.9 (99.7)
Redundancy 6.4 (5.9) 7.0 (7.0) 4.8 (4.9) 4.2 (4.3) 4.9 (4.6)
	Mean (I)/S.D.
 10.5 (2.1) 11.7 (2.9) 14.2 (2.3) 10.1 (2.3) 10.4 (1.8)
Rsym (%) 13.4 (67.9) 14.9 (63.5) 8.0 (69.5) 10.4 (59.5) 10.4 (66.8)
Rcryst (%) 21.5 21.8 23.3 21.9 22.6
Rfree (%) 25.4 25.6 27.1 25.3 27.0
r.m.s.d. bond length (Å) 0.007 0.008 0.008 0.008 0.007
r.m.s.d. bond angle (°) 1.23 1.12 1.22 1.16 1.15
Surface area buried on PCSK9-EGF(A) (Å2) 468/514 496/523 553/586 513/532 470/507
Protein Data Bank entry code 2W2M 2W2N 2W2O 2W2Q 2W2P
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our binding data suggest that the phenotype of the N157K
mutation is caused by a decreased affinity for the LDLR.
Molecular Basis for FH Associated with the LDLR H306Y
Mutation and pH Dependence of the PCSK9-EGF(AB)
Interaction—A comparison of the PCSK9C-EGF(AB) neutral
pH structure determined herein with the structure of the
PCSK9-EGF(AB) complex determined at low pH (20) shows
that although the structures are highly similar overall, EGF(A)
His-306 borders the binding interface but assumes a different
rotamer in the two structures. At low pH, His-306 forms an
intermolecular salt bridge with the PCSK9 Asp-374 side chain,
whereas at neutral pH, His-306 forms an intramolecular
H-bondwith the EGF(A) Ser-305 hydroxyl group (Fig. 5A). The
His-306—Asp-374 interaction may occur at low pH following
protonation of the His side chain upon traversing its pK of6.
Ensembles ofNMRsolution structures of EGF(AB) alone deter-
mined at either pH 5.5 (36) or pH 6.5 (37) all reveal a confor-
mation of His-306 similar to that observed here at neutral pH,
thus suggesting that the repositioning of His-306 requires both
low pH and stabilization by the concomitant formation of a salt
bridge with Asp-374. Importantly, the pH-dependent forma-
tion of this additional bond is consistent with the increased
affinity of the PCSK9-EGF(AB) interaction at low pH (Table 1).
The conformational rearrangements described above also
suggested that the naturally occurring LDLR mutation H306Y,
which is associated with familial hypercholesterolemia (23, 24),
may cause the FH phenotype by promoting enhanced PCSK9
binding. The crystal structure of PCSK9C bound to
EGF(AB)H306Y, which we also present here (Table 2), reveals
that the hydroxyl group of Tyr-306 forms an H-bond (2.8 Å)
with the side chain of PCSK9Asp-374 (Fig. 5B) and results in an
increased total buried surface area (1019Å2) comparedwith the
WT complex (982 Å2; Table 2). The Tyr-306—Asp-374
H-bond interaction is similar to the His-306—Asp-374 salt
bridge interaction observed in the low pH PCSK9-EGF(A)
structure. Moreover, when tested in the TR-FRET assay, the
EGF(AB)H306Y mutant showed an 3-fold enhanced binding
affinity compared with WT EGF(AB) (Table 3). Of note, the
Tyr-306 side chain hydroxyl group is expected to be available
for H-bonding with Asp-374 regardless of the pH. Indeed, SPR
studies showed that binding of PCSK9 to immobilized
EGF(AB)H306Y is insensitive to pH (data not shown).
We also introduced the H306Y mutation into the LDLR
ectodomain protein to assess whether it abolishes the pH
dependence of binding in the context of the full-length protein.
In SPR experiments, the full-length LDLRH306Y bound PCSK9
with a KD of 330 nM at neutral pH, with the affinity being
enhanced 50-fold (KD 7 nM) at acidic pH (Table 1). Therefore
although pH-dependent protonation of His-306 is responsible
for a modest 2–3-fold enhancement of binding affinity with
PCSK9, it does not explain the large pH dependence observed
for binding of PCSK9 to the full-length LDLR protein.
X-ray Crystal Structures of GOF PCSK9C-EGF(AB)
Complexes—Following characterization of the complex
between EGF(AB) and PCSK9C, we also determined the
structures at neutral pH of WT EGF(AB) bound to mutant
PCSK9C proteins harboring the naturally occurring GOF
mutations D374Y or D374H (Table 2), both of which have been
reported to cause severe hypercholesterolemia (21, 22). Overall
these structures are the same as the WT complex, with a C
atom r.m.s.d. of only 0.4Å.However, both structures reveal that
at neutral pH the Tyr-374 or His-374 side chain of PCSK9C
establishes an H-bond (3.2Å) with the backbone carbonyl
atom of EGF(A) Cys-319 (Fig. 5, C and D). There is also a con-
siderable increase (6–16%) in total buried surface area at the
interface due to packing of the aromatic side chain of PCSK9
residue His-374/Tyr-374 against EGF(A) Leu-318 (Table 2).
These additional interactions with EGF(A) may explain the
enhanced affinity of the PCSK9D374Y(H)-LDLR interactions
reported previously (10, 17) and indeed the severe hypercholes-
terolemia in carriers of suchmutations. Previously we reported
a mild GOF effect for PCSK9D374A (27). Not surprisingly the
EGF(AB)-PCSK9D374A structure (Table 2) does not reveal addi-
tional interactions of Ala-374 with EGF(AB). However, the
replacement of the negatively charged Asp-374 with the non-
FIGURE 4. Structural and functional role of the PCSK9 catalytic domain P
helix.A surface representation of the PCSK9C catalytic domain (gray) with a
ribbon representation for the P helix (pink), which is accommodated in a
deep pocket of the catalytic domain after autocleavage. Ser-153 at the N
terminus of the PCSK9 P helix makes a 2.9-Å salt bridge (shown as a dotted
line) with the side chain of Asp-299 (EGF(A) (yellow)). Pro-155 makes van der
Waals contacts with Leu-298 (EGF(A)). The EGF(A) Ca2 ion is shown as a
sphere and intramolecular disulfidebonds as stickswith sulfur ingreen). Single
pointmutations of residues shown on the P helix result in PCSK9C proteins
with reduced ability to disrupt the PCSK9-LDLR interaction in the TR-FRET
assay (Table 3).
TABLE 3
Summary of binding data from TR-FRET assay
Protein IC50
nM
PCSK9 80 23
PCSK9C 110 45
PCSK9CP155G 1241 518
PCSK9CW156L 1695 271
PCSK9CN157K 850 190
PCSK9CL158A 2500
PCSK9CI161A 293 2
PCSK9CR194A 2500
PCSK9CD238A 2500
PCSK9CS386Aa No inhibition
LDLR ectodomain 214 41
LDLR EGF(A) 1255 7
LDLR EGF(AB) 367 94
LDLR EGF(AB)H306Y 140 50
a Unprocessed PCSK9C due to mutation of the catalytic Ser-386 to alanine. All
other PCSK9 and PCSK9C proteins were fully processed (autocleaved).
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polar Ala-374 may favor formation of the interface, given the
hydrophobic nature of the environment around EGF(AB) resi-
dues Val-307 and Leu-318 (supplemental Fig. 2).
Functional Characterization of
EGF(A)andEGF(AB)WTandH306Y
Mutant—Previous work has estab-
lished that the addition of purified
mature PCSK9 to themedium of cul-
tured cells causes a lowering of LDL
uptake due to a down-regulation of
LDLR protein levels (9, 14, 17). To
determine whether the EGF(A) and
EGF(AB) repeats could inhibit the
LDLR-lowering activity of exog-
enously added PCSK9, we tested the
effect of these two proteins in a cellu-
lar LDL uptake assay. Here we dem-
onstrated that isolated EGF(A) and
EGF(AB) proteins are sufficient to
inhibit the LDLR-lowering effect of
purifiedPCSK9addedexogenously to
cultured cells, with IC50 values of
5.4  1.5 and 1.5  0.5 M, respec-
tively. Moreover, the mutant
EGF(AB)H306Y protein was an even
more potent inhibitor of PCSK9
(IC50 0.8M) (Fig. 6). These values
reflect the relative potencies reported
above for inhibition of the PCSK9-
LDLR interaction by EGF(A),
EGF(AB), and EGF(AB)H306Y in the
TR-FRET assay.
DISCUSSION
The identification of mutations
in PCSK9 that are associated with
either hypercholesterolemia or hypocholesterolemia has
generated a great interest in the biology of PCSK9 and its
mechanism of action. As for other convertases, PCSK9
undergoes an autocleavage event that is required for its
secretion (8, 9). Following autocleavage, the protease activity
of mature PCSK9 appears to be self-inhibited by the prodo-
main, which remains stably associated with the rest of the
protein (10–12). Mature PCSK9 acts by binding to LDLR at
the cell surface and subsequently promoting internalization
and degradation of the receptor, an activity that is independ-
ent of its catalytic triad (34, 38). The binding of PCSK9 to
LDLR is therefore fundamental in reducing receptor levels.
Here we report a biochemical, structural, and functional
characterization of this interaction, thus providing insight
into molecular determinants governing the regulation of cir-
culating LDL levels.
It has been shownpreviously that the EGF(A) repeat of LDLR
is sufficient for PCSK9 binding (19, 20). Moreover, our binding
studies indicate that the PCSK9 C-terminal domain is not
involved in the interaction with LDLR, as a PCSK9C protein
lacking this region of the protein showed approximately the
same affinity for the receptor as full-length PCSK9. Thus, to
characterize the molecular details of the interaction between
PCSK9 and LDLR, we crystallized the PCSK9C-EGF(AB)
complex at neutral pH. In the structure the EGF(A) domainwas
FIGURE 5. Involvement at the binding interface of LDLR residue 306 and PCSK9 residue 374. A, electron
density map (2Fo  Fc) refined to 2.4 Å resolution (contoured at 1.5 ), showing WT EGF(A) (yellow) and
PCSK9C (gray) from the structure presented here at neutral pH. The His-306 side chain N atom forms a 2.8 Å
hydrogenbondwith the Ser-305 side chain; theN atom is9Å away fromAsp-374 of PCSK9. In contrast is the
conformation of the His-306 residue (thin sticks,white) from the superimposed PCSK9-EGF(A) structure deter-
mined at pH 4.8 (20). In the latter, the N group is3.9 Å from the side chain of Asp-374, presumably enabling
formation of a salt bridge in the protonated state at low pH. There is no electron density visible for this low pH
rotamer conformation in themap determined herein. B, electron densitymap refined to 2.3 Å resolution (1.5
contour), showing EGF(AB)H306Y (orange) and PCSK9C (gray) from the structure presented here at neutral pH.
The Tyr-306 side chain does not form an H-bond to Ser-305 but rather forms a 2.8Å hydrogen bond with
Asp-374of PCSK9. The conformationof Tyr-306 at neutral pH is thus comparablewith that ofHis-306 at lowpH.
C, electron density map refined to 2.62 Å (1  contour) for EGF(AB) bound to the PCSK9C D374Y mutant,
showing theH-bond between Tyr-374 and Cys-319. As shown in A, His-306 of EGF(AB) forms an intramolecular
bondwith Ser-305.D, electrondensitymap refined to 2.33Å (1.5 contour) for EGF(AB) bound to the PCSK9C
D374Hmutant, showing the H-bond between His-374 and Cys-319.
FIGURE 6. Functional characterization of EGF(A), EGF(AB), and
EGF(AB)H306Y in a cell-based LDL uptake assay. WT PCSK9 (pink cross)
strongly reduces the amount of LDL uptake compared with background
(black-filled circle). EGF(A) (green square), EGF(AB) (red triangle), and
EGF(AB)H306Y (blue triangle) inhibit the effect of WT PCSK9. The effect of sol-
uble LDLR ectodomain could not be measured in this assay because of its
intrinsic ability to bind LDL.
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found to contact only the catalytic domain of PCSK9 in prox-
imity to a -hairpin loop containing residue Asp-374. A natu-
rally occurring D374Y GOF mutation conferred a higher affin-
ity of binding to the LDLR. The observed mode of binding was
consistent with our biochemical and functional data. Indeed,
despite its small size, the EGF(A) repeat (40 amino acids) com-
peted efficiently with full-length LDLR ectodomain (766 amino
acids) for binding to PCSK9. We note that in our TR-FRET
assay, EGF(AB) (80 residues) was slightly more potent than
EGF(A); it is likely that this difference was due to the greater
structural stability of the EGF(AB) protein rather than to a sig-
nificant increase in the number of residues directly involved in
binding.
Apanel ofmutant PCSK9Cproteinswas produced to assess
the contribution of single amino acids at the complex interface
for high affinity binding. This approach further validated the
structural findings and confirmed the key role of PCSK9 Arg-
194, which binds to EGF(A) Asp-310, and PCSK9 Asp-238,
which forms a hydrogen bond with EGF(A) Asn-295. In addi-
tion the structure and mutagenesis data suggested an essential
role in LDLR binding for the P -helix at the N terminus of the
PCSK9 catalytic domain. Indeed, PCSK9C proteins contain-
ing mutations predicted to affect the position and/or structure
of this -helix were found to undergo normal autoprocessing
but were defective in LDLR binding. Among these mutants is
the naturally occurringN157Kvariant, thus providing an expla-
nation for the associated LOF phenotype.
The interaction of PCSK9with EGF(A) has been shown to be
pH-dependent (19, 20). Our SPR studies confirmed that the
EGF(AB) domain has an increased binding affinity for PCSK9 at
low pH, although this increase was smaller than that observed
for the full-length LDLR ectodomain (i.e. 3-fold versus 100-
fold). The increased affinity of the interaction at acidic pH is of
mechanistic relevance, and therefore residues responsible for
this behavior are of particular interest. Although most of the
intermolecular contacts aremediated by polar residues that are
unlikely to change their protonation state when moving from
physiological pH to acidic pH, a histidine of EGF(A), His-306, is
located at the border of the EGF(A) region binding PCSK9.
Because histidine side chains typically have a pK value of 6,
the amino acid His-306 has been suggested to mediate the pH
dependence of PCSK9-EGF(AB) binding (20). At the neutral
pH of our structure, the side chain of His-306 is presumably
unprotonated, and the N atom accepts an intramolecular
H-bond (2.8Å) from the side chain OH group of Ser-305 (Fig.
5A). This arrangement differs from the conformation adopted
by theHis-306 side chain in the crystal structure of the complex
between WT PCSK9 and EGF(AB) determined at pH 4.8 (20).
In the low pH structure, His-306 does not form anH-bondwith
Ser-305 but rather points toward PCSK9 Asp-374. At pH 4.8, it
is highly likely that His-306 becomes protonated and positively
charged, thereby allowing formation of a salt bridge (3.5–4.0Å)
with the carboxylate group of Asp-374. Formation of this inter-
action also results in an increase in total buried surface. The
stabilization of this alternative rotamer conformation of His-
306 appears to be dependent on the presence of PCSK9,
because inNMR structures determined previously at pH5.5 the
His-306 side chain is in a position similar to the one observed
here at neutral pH. The pH-dependent formation of the addi-
tional salt bridge and increase in buried surface area represents
a potential mechanism for affinity enhancement of the PCSK9-
EGF(A) interaction during endocytosis and transfer of the com-
plex from neutral pH to the acidic pH of the endosomes.
The model described above suggests that the pH-depend-
ent enhancement of the PCSK9-EGF(A) interaction is linked
to the formation of a salt bridge between Asp-374 and His-
306 and to an increase in the total buried surface of the
complex. This hypothesis is supported by the structures of
PCSK9C-EGF(AB)H306Y, PCSK9CD374Y-EGF(AB), and
PCSK9CD374H-EGF(AB) complexes obtained at neutral
pH. In the PCSK9C-EGF(AB)H306Y structure, the Tyr-306
side chain adopts a rotamer conformation similar to the one
observed for His-306 in the low pH PCSK9-EGF(AB) com-
plex and with its hydroxyl group establishes a hydrogen bond
with the Asp-374 side chain (Fig. 5B). When tested in the
TR-FRET assay, this EGF(AB) mutant showed a 3-fold
enhancement in affinity for PCSK9, further confirming that
formation of a bond with PCSK9 Asp-374 results in a tighter
association of the complex. Importantly, the increased
PCSK9 binding activity of EGF(AB)H306Y is in close agree-
ment with the 3-fold enhancement at pH 5.6–6.0 of the
PCSK9-EGF(AB) affinity (Ref. 20 and this study). Similar
to the PCSK9C-EGF(AB)H306Y complex, in the
PCSK9CD374Y-EGF(AB) complex an additional hydrogen
bond is formed between the Tyr-374 hydroxyl group and the
carbonyl oxygen of EGF(A) Cys-319. Further, there is a sig-
nificant (16%) increase in the total buried surface area due to
the involvement of the large Tyr-374 side chain. Together
these observations may explain the 6–30-fold tighter LDLR
binding of this PCSK9 GOF mutant compared with the WT
protein at neutral pH (10, 17). A similar interaction is estab-
lished by the His-374 side chain in the PCSK9CD374H-
EGF(AB) complex, presumably explaining the GOF pheno-
type associated with this FH mutant PCSK9.
The interaction between PCSK9D374Y and EGF(AB) is also
pH-dependent (supplemental Fig. 1B) (10, 17). As proposed
previously (20), at acidic pH the protonated EGF(A) His-306
side chain may adopt the conformation observed in the low pH
PCSK9-EGF(AB) structure, thus establishing an intermolecular
hydrogen bond to PCSK9 Tyr-374. The interaction between
Tyr-374 and His-306 could be shorter (2.9Å) than that estab-
lished at neutral pHwithCys-319 (3.2Å) andwould also cause
a further increase in the total buried surface, potentially
explaining the enhancement in binding affinity at acidic pH for
this complex. Thus, formation of an H-bond at neutral pH
between Asp-374 and EGF(A) Tyr-306, or between Tyr-374 or
His-374 and the carbonyl oxygen of EGF(A) Cys-319, and for-
mation of a salt bridge at low pH between Asp-374 and EGF(A)
His-306 have similar effects in increasing the affinity of the
complex. Nevertheless, we note that mutation of Asp-374 into
Ala or Phe has also been reported to result in an increased
affinity for the LDLR (27) suggesting that other factors, such as
electrostatic effects, might also modulate the affinity of the
complex.
Together these data support the notion that the protonation
of EGF(A) His-306 and formation of an intermolecular salt
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bridge with Asp-374 are responsible for the pH dependence of
the PCSK9-EGF(A) interaction. Consistently, in SPR experi-
ments we found that the affinity of the PCSK9-EGF(AB)H306Y
interaction is pH-independent (data not shown; see “Results”).
Importantly a 50-fold increase in PCSK9 binding at low pH
compared with neutral pH was observed when studying the
same H306Y mutation in the full-length LDLR ectodomain,
demonstrating that additional factors contribute to the large
increase in affinity of the PCSK9-LDLR complex observed at
low pH. Changes in the conformation of the LDLR and
increased accessibility of the EGF(A) domain to PCSK9, as
indicated by a faster association constant (kon) at low pH
compared with neutral pH (Table 1 and Ref. 17), may in part
explain the large increase in binding affinity observed at
acidic pH. Moreover, the much greater affinity at acidic pH
seen for the PCSK9-LDLR complex compared with PCSK9-
EGF(AB) complex points to additional factors, such as an
increased number of contacts or greater structural rigidity of
the EGF(A) domain within the full-length LDLR, which may
play a role in the interaction.
In an extension of our biochemical analyses to a cellular con-
text, we also demonstrated that EGF(A) and EGF(AB) are suf-
ficient to inhibit the LDLR-lowering activity of PCSK9 in a cell-
based assay that monitors the uptake of LDL. In the same
functional assay the EGF(AB)H306Y mutant was even more
potent than EGF(AB), supporting our structural and biochem-
ical results. Importantly, this is the first demonstration that the
activity of exogenous PCSK9 can be inhibited by direct compe-
tition of its interaction with LDLR. Of note, epitope excision
and mass spectrometry using PCSK9 and the PCSK9-EGF(AB)
complex revealed that PCSK9 residues 175–210 remain bound
to EGF(AB) after protease treatment and washing, suggesting
that they bind tightly to EGF(AB). It will be interesting to test
whether peptides based on this single region of the PCSK9 cat-
alytic domain may bind the EGF(A) domain with sufficiently
high affinity to interfere with the PCSK9-LDLR interaction.
Likewise, peptidic fragments of EGF(A) might bind PCSK9 and
have inhibitory potential.
In summary, the results presented herein provide themolec-
ular basis for the interaction of PCSK9 with the LDLR EGF(A)
domain occurring at the cell surface at neutral pH. The struc-
tures of several complexes containing mutations associated
with FH reveal the mechanism for enhanced PCSK9-LDLR
interactions leading to gain-of-function phenotypes and hyper-
cholesterolemia. Further, the structural and biochemical data
lead to a plausible model for the determinants of the pH depend-
ence of this interaction. Finally, we have demonstrated that the
EGF subfragments of the LDLR are able to counteract the inhibi-
tory effect of PCSK9 in LDL uptake assays, but further efforts are
required to employ the structural and biochemical data presented
herein for the development of disruptors of the PCSK9-LDLR
interaction that appear to hold therapeutic promise.
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